<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391413</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00532-37</org_study_id>
    <nct_id>NCT04391413</nct_id>
  </id_info>
  <brief_title>Does OCT Optimise Results of Stenting on the Left Main Stem</brief_title>
  <acronym>DOCTORS-LM</acronym>
  <official_title>Does Optical Coherence Tomography Optimise Results of Stenting of the Left Main Stem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DOCTORS-LM study will investigate the impact of using optical coherence tomography (OCT)&#xD;
      to guide the procedure in angioplasty of lesions of the left main stem responsible for&#xD;
      myocardial ischemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Angiographic evaluation of lesions of the left main stem presents particular challenges and&#xD;
      high procedural complexity. The clinical sequelae of a suboptimal result in this context may&#xD;
      be severe, and thus, it is recommended that patients with left-main lesions be considered for&#xD;
      imaging-guided interventions by means of optimal coherence tomography (OCT) in non-ostial&#xD;
      left main lesions. The investigators have previously demonstrated in a randomized trial of&#xD;
      patients undergoing PCI for a lesion responsible for non ST elevation acute coronary&#xD;
      syndromes that OCT provides useful clinical information beyond that obtained by angiography&#xD;
      alone, and OCT-guidance for angioplasty in these patients yielded a significantly higher&#xD;
      proportion of patients with an optimal functional result after stenting. In this context, the&#xD;
      aim of the present study is to evaluate whether OCT-guided left-main angioplasty is superior&#xD;
      to left main angioplasty guided by fluoroscopy alone, as assessed by fractional flow reserve&#xD;
      (FFR) measured after stent implantation. Eligible patients must be aged 18 years and over,&#xD;
      admitted for acute coronary syndrome (ACS) or stable coronary artery disease (CAD); AND&#xD;
      present an angiographically significant non-ostial lesion of the left main stem requiring&#xD;
      angioplasty with drug eluting stent implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">August 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional outcome of the procedure (absolute value)</measure>
    <time_frame>At the end of the procedure, once the operator judges the result to be satisfactory.</time_frame>
    <description>Functional outcome as assessed by the Fractional flow reserve (FFR) at the end of the procedure (average of at least 3 consecutive measures)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional outcome of the procedure (dichotomized)</measure>
    <time_frame>At the end of the procedure, once the operator judges the result to be satisfactory.</time_frame>
    <description>Percentage of patients with a final fractional flow reserve (FFR) value &gt;=0.90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in final FFR value</measure>
    <time_frame>At the end of the angioplasty procedure</time_frame>
    <description>Relative change in final FFR value as compared to initial FFR value at the start of the procedure in each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in whom OCT after stent implantation reveals a suboptimal result</measure>
    <time_frame>Immediately after stent implantation</time_frame>
    <description>Percentage of patients in whom OCT after stenting reveals a sub-optimal result, defined as the presence of any one or more of the following criteria:&#xD;
Stent under expansion&#xD;
Stent malapposition&#xD;
Lesion incompletely covered by the stent&#xD;
Residual stenosis upstream or downstream of the stent&#xD;
Edge dissection&#xD;
Thrombus&#xD;
Tissue protrusion through the stent struts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in whom a change in procedural strategy is decided based on OCT data</measure>
    <time_frame>Immediately after stent implantation</time_frame>
    <description>Percentage of patients in whom a change in procedural strategy is decided based on OCT data, with use of any one or more of the following:&#xD;
GPIIb/IIIa inhibitors&#xD;
Thrombo aspiration&#xD;
Rotational atherectomy&#xD;
Additional stent implantation&#xD;
Additional balloon inflations&#xD;
Re-opening of strent struts in secondary branch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of OCT in angioplasty of the left main stem</measure>
    <time_frame>At the end of the angioplasty procedure</time_frame>
    <description>Safety of OCT in angioplasty of the left main stem, as assessed by duration of procedure (minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of OCT in angioplasty of the left main stem</measure>
    <time_frame>At the end of the angioplasty procedure</time_frame>
    <description>Safety of OCT in angioplasty of the left main stem, as assessed by - fluoroscopy time (minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of OCT in angioplasty of the left main stem</measure>
    <time_frame>At the end of the angioplasty procedure</time_frame>
    <description>Safety of OCT in angioplasty of the left main stem, as assessed by Radiation dose received (MSv)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of OCT in angioplasty of the left main stem</measure>
    <time_frame>At the end of the angioplasty procedure</time_frame>
    <description>Safety of OCT in angioplasty of the left main stem, as assessed by Quantity of contrast medium used (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of OCT in angioplasty of the left main stem</measure>
    <time_frame>At the end of the angioplasty procedure</time_frame>
    <description>Safety of OCT in angioplasty of the left main stem, as assessed by change in creatinine clearance over the first 24 hours (Creatinine clearance in ml/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of OCT in angioplasty of the left main stem</measure>
    <time_frame>At the end of the angioplasty procedure</time_frame>
    <description>Safety of OCT in angioplasty of the left main stem, as assessed by procedural complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT data that predict final FFR value &gt;=0.90</measure>
    <time_frame>At the end of the angioplasty procedure</time_frame>
    <description>Thresholds for minimal lumen diameter and minimal stent area on OCT that best predict a final FFR value &gt;=0.90</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Non ST Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>OCT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCT will be performed after initial coronary angiography and at the end of the procedure. Several OCT runs can be performed. The operator may change procedural strategy, and use additional interventions. The operator must evaluate the following parameters, based on OCT data:&#xD;
Before angioplasty: reference diameter and reference area of distal main vessel; lesion length; presence and extent of thrombus or calcification.&#xD;
Stent implantation: Stent should be sized according to distal reference diameter, and should allow for expansion to the reference diameter of the proximal main vessel.&#xD;
After stent implantation: minimal and reference lumen diameter, minimal and reference lumen area, minimal stent area, presence of thrombus, presence of edge dissection, tissue protrusion, optimal lesion coverage, malapposition, suboptimal stent deployment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Angioplasty will be guided by traditional fluoroscopy alone, performed before and after stent implantation. The recommendation for angioplasty of left main stenosis is to use main vessel (MV) stenting with a proximal optimisation technique (POT) and provisional side branch (SB) stenting as a preferred approach. Predilatation of the side branch (SB) may be considered, but is recommended in the following circumstances: extensive ostial SB involvement, heavy calcification, etc. even with a provisional SB stenting approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Use of OCT to guide the angioplasty procedure</intervention_name>
    <description>OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.</description>
    <arm_group_label>OCT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients aged 18 years or over presenting with:&#xD;
&#xD;
          -  NSTEMI or unstable angina or stable angina or documented silent ischemia AND&#xD;
&#xD;
          -  De novo angiographic lesion (% diameter stenosis &gt;=50%) or functionally significant&#xD;
             (FFR&lt;=0.80) lesion of the left main stem (median or distal) with or without lesions of&#xD;
             the ostia of the LAD and/or circumflex arteries (= Medina classification 1-0-0, 1-0-1,&#xD;
             1-1-0, 1-1-1) or ostial lesion of the LAD and/or circumflex artery requiring&#xD;
             angioplasty with stent implantation that will cover the distal left main stem (=Medina&#xD;
             classification 0-0-1, 0-1-0 ou 0-1-1) AND&#xD;
&#xD;
          -  SYNTAX score ≤ 22 (or &gt;22 and ≤32 and validated by the Heart Team)&#xD;
&#xD;
          -  Lesion with reference angiographic diameter &lt;=5.5mm&#xD;
&#xD;
          -  Signature of written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with:&#xD;
&#xD;
          -  ST segment elevation myocardial infarction&#xD;
&#xD;
          -  Ostial lesion of the left main stem&#xD;
&#xD;
          -  Technically impossible to perform OCT&#xD;
&#xD;
          -  Creatinine clearance ≤ 30 ml/min/1.73m²&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          -  Hypotension or cardiogenic shock&#xD;
&#xD;
          -  Unstable ventricular arrhythmia&#xD;
&#xD;
          -  Contraindication to dual antiplatelet therapy for at least 6 (or 12) months (duration&#xD;
             depending on the initial clinical presentation). Shorter dual antiplatelet therapy is&#xD;
             possible in patients with long-term anticoagulation.&#xD;
&#xD;
          -  Hypersensitivity or contraindication to any of the antithrombotic therapies used&#xD;
             during or after the procedure&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  Persons under judicial protection&#xD;
&#xD;
          -  Subjects with no social security coverage&#xD;
&#xD;
          -  Anticipated non-compliance with the study procedures&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Subjects within the exclusion period of another clinical trial&#xD;
&#xD;
          -  Failure to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Meneveau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Department, CHU Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas F Meneveau, MD, PhD</last_name>
    <phone>33381668539</phone>
    <email>nicolas.meneveau@univ-fcomte.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fiona Ecarnot, PhD</last_name>
    <phone>33381668539</phone>
    <email>fiona.ecarnot@univ-fcomte.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Besancon</name>
      <address>
        <city>Besançon</city>
        <state>Please Select</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Ecarnot, PhD</last_name>
      <phone>33381668539</phone>
      <email>fiona.ecarnot@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Francois Schiele, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain Chopard, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion Chatot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <state>Please Select</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Van Belle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Saint Martin</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Morelle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Chartres - Hôpital Louis Pasteur</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grégoire Rangé, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Motreff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Cardiovasculaire Paris Sud</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lefevre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes - Hôpital Carémeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Cayla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Amabile, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Levesque, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Hilaire</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René Koning, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Arnault Tzanck</name>
      <address>
        <city>Saint-Laurent-du-Var</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Adjedj, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Trévenans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoann Lefrançois, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P, Morel O, Lefrançois Y, Descotes-Genon V, Silvain J, Braik N, Chopard R, Chatot M, Ecarnot F, Tauzin H, Van Belle E, Belle L, Schiele F. Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting). Circulation. 2016 Sep 27;134(13):906-17. doi: 10.1161/CIRCULATIONAHA.116.024393. Epub 2016 Aug 29.</citation>
    <PMID>27573032</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>left main stem</keyword>
  <keyword>angioplasty</keyword>
  <keyword>optical coherence tomography</keyword>
  <keyword>myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

